|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Focal and Segmental Glomerulosclerosis (FSGS) Eval
Test CodeCPT Codes
81405, 81406 (x3)<br>Limited Access Code
Physician Attestation of Informed Consent
Includes
Preferred Specimen
Pediatric volume: 2 mL whole blood
Minimum Volume
Instructions
Informed consent required
Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
Higher blood volumes ensure adequate DNA quantity, which varies with WBC, specimen condition, and need for confirmatory testing. Patients, 0-3 years have higher WBC, yielding more DNA per mL of blood.
Hemolysis may compromise DNA recovery and integrity after 48 hours.
Shipping Conditions: Ship room temperature, avoid freezing
Transport Temperature
Specimen Stability
Refrigerated: 10 days
Frozen: Unacceptable
Methodology
Sanger Sequencing
FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Reference Range
Clinical Significance
Disease(s) tested for: Nephronic Syndrome, Focal segmental glomerulosclerosis
Detects mutations in the INF2, SCTN4, TRPC6, and NPHS2 genes.
Detects sequence variants in the INF2, ACTN4, TRPC6, and NPHS2 genes in patients with nephrotic syndrome. Patients exhibit proteinuria, nephrotic syndrome, and frequently the progressive loss of renal function.